– Novel Construct for Two Investigational Therapies Could Enable Safer, More Effective and Accessible CAR Ts – SANTA MONICA, Calif., December 06, 2025--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: ...
Kite, a Gilead Company (GILD), presented Phase 1 data with efficacy and safety results for its two investigational bicistronic CAR T-cell therapies, KITE-753 and KITE-363, respectively, in patients ...
– Initial Results from Kite-753, Optimized with Novel Manufacturing Process That Preserves T-Cell Fitness, Show High Complete Response Rate and Favorable Safety Trend – – Novel Construct for Two ...
Kite’s Next-Generation Bicistronic CAR T-Cell Therapies Show Encouraging Phase 1 Results in Relapsed/Refractory B-Cell Lymphoma in New Data at ASH 2025 – Initial Results from Kite-753, Optimized with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback